166 Single Centre Experience with Heart Function Clinic and Heart Failure Admissions

Abstract

Background: SGLT2 inhibitors are associated with a lower risk of cardiovascular events and hospitalisation from heart failure in patients with high cardiovascular risk, in addition to offering glycaemic control (1-3). Aim: To provide a snapshot of the use of SGLT2 inhibitors in heart failure patients with reduced ejection fraction (HFrEF) and type 2 diabetes.